Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up.

ABSTRACT: In a previous phase 3 clinical trial, a 23-valent pneumococcal polysaccharide vaccine (PPV23) induced robust immune responses in participants aged 2 years and older. We conducted this study to evaluate the immune persistence of a single dose of PPV23 6 years after vaccination. In this follow-up study, 600 participants aged 2 years and older (referred to the age of vaccination) who had received a single dose of either test vaccine or control vaccine in the previous clinical trial were enrolled in a 3:1 ratio. Blood samples were collected to determine anti-capsular immunoglobulin G (IgG) antibody levels against 23 serotypes with enzyme-linked immunosorbent assay (ELISA). A total of 598 subjects were included for immune persistence analysis. Six years after vaccination, the geometric mean con

SUBMITTER: Huang L 

PROVIDER: S-EPMC12184158 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature